argenx SE (ARGX) ADR Each Representing 1 Ord Share SPON
Sell:$654.61Buy:$655.82
$7.77
(1.20%)
0.51%- This stock can be held in a
Stocks and Shares ISA$7.77
(1.20%)$7.77
(1.20%)Company Information
About this company
argenx SE, formerly arGEN X BV, is a Netherlands-based biopharmaceutical company. It is primarily engaged in creating and developing a pipeline of differentiated antibody therapeutics for the treatment of severe autoimmune diseases using its discovery platform, Simple Antibody, which exploits characteristics of the llama immune system. The Company develops a pipeline of antibody therapeutics focused on cancer and autoimmune indications. It includes, but is not limited to: Empasiprubart, a complement inhibitor targeting C2, blocking the function of both the classical and lectin pathways, while leaving the alternative pathway intact, ARGX-119 an antagonist to the MuSK receptor with potential in multiple neuromuscular indications.
Key people
Key facts
- EPIC-
- LocationNetherlands
- SectorHealthcare
- IndustryBiotechnology & Drugs
- ISINUS04016X1019
- Market cap$40.04bn
- Employees1,148
- Shares in issue60.76m
- ExchangeEuronext Brussels
- IndexBEL 20 Index
- Website
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.